GSK’s first lung cancer approval, a new IPO path and more

The biopharma industry is navigating a period of significant regulatory, clinical, and financial evolution. Legislative efforts in the U.S. House are pushing the FDA to modernize drug testing by incorporating computational models and organoids, potentially shifting the preclinical research landscape away from traditional animal studies. In the commercial sector, GSK’s rapid FDA approval of the lung cancer drug Jodetro—secured just one week after acquiring Nuvalent—highlights the strategic value of late-stage biotech assets. Meanwhile, the public markets are showing renewed vigor with a surge in biotech IPOs, yet companies like Axiom Biosciences are challenging traditional norms by pursuing unconventional co-listings in Hong Kong and the NASDAQ to access specialized investor bases. These developments collectively signal a system in flux, where advancing technology and shifting capital flows are redefining how new medicines are developed and financed.